Trial Profile
Study of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2016
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Lung cancer
- Focus Biomarker; Therapeutic Use
- 14 Nov 2016 New trial record